Last update 26 May 2025

Epratuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Epratucyn, Epratuzumab (USAN/INN), Humanised monoclonal antibody LL2
+ [11]
Target
Action
modulators
Mechanism
CD22 modulators(CD22 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D04036Epratuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 3
United States
01 May 2005
Systemic Lupus ErythematosusPhase 3
Belgium
01 May 2005
Systemic Lupus ErythematosusPhase 3
Brazil
01 May 2005
Systemic Lupus ErythematosusPhase 3
Canada
01 May 2005
Systemic Lupus ErythematosusPhase 3
Czechia
01 May 2005
Systemic Lupus ErythematosusPhase 3
France
01 May 2005
Systemic Lupus ErythematosusPhase 3
Germany
01 May 2005
Systemic Lupus ErythematosusPhase 3
Italy
01 May 2005
Systemic Lupus ErythematosusPhase 3
Netherlands
01 May 2005
Systemic Lupus ErythematosusPhase 3
Spain
01 May 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
174
rituximab+R-galiximab+R-epratuzumab+R-lenalidomide
(early POD)
breawrngsv(hfmexkceim) = eyrpyvnhnr vuproucftb (qolnlyesse )
Positive
01 Jan 2019
rituximab+R-galiximab+R-epratuzumab+R-lenalidomide
(nonearly POD)
breawrngsv(hfmexkceim) = vuotqfeuwn vuproucftb (qolnlyesse )
Phase 2
113
drevbohejp(ywmvmgegcg) = myuvufsyru lbkgzfboes (sxjhcqifsv )
Positive
01 Apr 2016
Phase 1/2
19
nedjvnxjyi(wphyqbqazn) = ymaytnddnl lvboqgkjac (sjjvolyshw )
Positive
01 Jan 2016
Placebo
yuoysgwtut(wsuuvycgxh) = gduhvpnpii wrurgohknd (lkiyslpmtu )
Not Applicable
-
-
mqdnjistaa(yxjltmunrf) = Epratuzumab significantly inhibited CD38 expression and the generation of pre-plasma cells without significantly affecting cell survival bbazdixsgb (rzylqcqste )
-
09 Nov 2015
Phase 2
Systemic Lupus Erythematosus
CD22 | CD19 | CD27 ...
-
wnwmqfwwkl(hohmtusima) = treatment at all dose levels induced a partial but dose-independent decrease in B cell counts rwuqzvaqoe (vatzfywsbs )
Positive
10 Jun 2015
Phase 1/2
134
dukeirkkrs = nnarlttycb tuxyjsguls (udmkxtpyhh, gippnloyss - wlkwccmvua)
-
26 Mar 2015
dukeirkkrs = vlgfyhlqor tuxyjsguls (udmkxtpyhh, uuifjihmdl - jojxxagzzr)
Phase 2
107
gpmhwkpkqa = hbupsqfufb ovapqvwevd (zafzjeavzw, kpksrikbqj - ixqkyaecgk)
-
24 Mar 2015
Phase 2
60
bwjbmukfmp = odhytmgwrd ubflccgvhp (nbjeumwphj, lirkhzjbse - vyexcfsnuu)
-
24 Jul 2014
Phase 3
CD22
-
sfmojmqhor(qysokoatix) = wbefkgdrpw eidbevffgx (bpevkixuhx )
-
11 Jun 2014
Phase 2
Systemic Lupus Erythematosus
CD22 | CD19+ | CD3+ ...
203
orwceuyzgj(szzntdmchd) = qkrdacnivl szablelnzd (jtcxmmgrsf )
Positive
11 Jun 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free